Jacqualyn Fouse - Feb 18, 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Signature
/s/ William Cook, as Attorney-in-fact for Jacqualyn Fouse
Stock symbol
AGIO
Transactions as of
Feb 18, 2022
Transactions value $
-$106,840
Form type
4
Date filed
2/23/2022, 03:10 PM
Previous filing
Feb 16, 2022
Next filing
Apr 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $0 +12.4K +18.7% $0.00 78.6K Feb 18, 2022 Direct
transaction AGIO Common stock Tax liability -$107K -3.67K -4.68% $29.08 74.9K Feb 22, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Performance share units Options Exercise $0 -12.4K -50% $0.00 12.4K Feb 18, 2022 Common stock 12.4K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
F2 The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.